Genprex (GNPX) Competitors

Genprex (NASDAQ:GNPX) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.

Do insiders & institutionals have more ownership in GNPX or AVTX?

9.1% of Genprex shares are owned by institutional investors. Comparatively, 67.5% of Avalo Therapeutics shares are owned by institutional investors. 10.6% of Genprex shares are owned by insiders. Comparatively, 45.4% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has higher valuation & earnings, GNPX or AVTX?

Genprex has higher earnings, but lower revenue than Avalo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$23.74 million	N/A	N/A
Avalo Therapeutics	$18.05 million	2.10	-$41.66 million	-$2.93	-0.98

Does the media prefer GNPX or AVTX?

In the previous week, Genprex had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 7 mentions for Genprex and 4 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.56 beat Genprex's score of 0.52 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genprex	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Avalo Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, GNPX or AVTX?

Genprex has a beta of -0.35, suggesting that its share price is 135% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Does the MarketBeat Community prefer GNPX or AVTX?

Genprex received 192 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 64.90% of users gave Genprex an outperform vote while only 30.77% of users gave Avalo Therapeutics an outperform vote.

Company	Underperform	Outperform
Genprex	Outperform Votes 196 64.90%	Underperform Votes 106 35.10%
Avalo Therapeutics	Outperform Votes 4 30.77%	Underperform Votes 9 69.23%

Is GNPX or AVTX more profitable?

Genprex has a net margin of 0.00% compared to Avalo Therapeutics' net margin of -170.36%. Genprex's return on equity of -109.81% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-109.81%	-97.89%
Avalo Therapeutics	-170.36%	-950.78%	-85.46%

Do analysts prefer GNPX or AVTX?

Genprex presently has a consensus price target of $3.00, suggesting a potential upside of 273.51%. Avalo Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 440.07%. Given Avalo Therapeutics' higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Genprex beats Avalo Therapeutics on 8 of the 15 factors compared between the two stocks.